Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation - Wikidata - wikimedia - TriplyDB

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

http://www.wikidata.org/entity/Q28306851

about

"Is dopamine involved in Alzheimer's disease?"Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease.Bushen‑Yizhi formula ameliorates cognition deficits and attenuates oxidative stress‑related neuronal apoptosis in scopolamine‑induced senescence in mice Back to the future with phenotypic screening Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients.Apomorphine and Alzheimer Aβ: roles for regulated α cleavage, autophagy, and antioxidation?SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease The Components of Flemingia macrophylla Attenuate Amyloid β-Protein Accumulation by Regulating Amyloid β-Protein Metabolic Pathway.Toxicity in rat primary neurons through the cellular oxidative stress induced by the turn formation at positions 22 and 23 of Aβ42.Dopamine D2 receptor and β-arrestin 2 mediate Amyloid-β elevation induced by anti-parkinson's disease drugs, levodopa and piribedil, in neuronal cells Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease.Sodium Tanshinone IIA Sulfonate Attenuates Scopolamine-Induced Cognitive Dysfunctions via Improving Cholinergic System Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits.CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease.A review: treatment of Alzheimer's disease discovered in repurposed agents.Establishment of experimental models for Alzheimer's disease research.Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer's disease.What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.Role of apomorphine in the treatment of Parkinson's disease.Catecholamine-Based Treatment in AD Patients: Expectations and Delusions.SIRT1 Overexpression in Mouse Hippocampus Induces Cognitive Enhancement Through Proteostatic and Neurotrophic Mechanisms.Cognitive decline in Parkinson disease.Monoaminergic neuropathology in Alzheimer's disease.UPS Activation in the Battle Against Aging and Aggregation-Related Diseases: An Extended Review.New Therapeutic Strategies for Lewy Body Dementias.Bushen-Yizhi formula ameliorates cognitive dysfunction through SIRT1/ER stress pathway in SAMP8 mice.Cytoplasmic superoxide radical: a possible contributing factor to intracellular Aβ oligomerization in Alzheimer disease.A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease Synthetic Fragment of Receptor for Advanced Glycation End Products Prevents Memory Loss and Protects Brain Neurons in Olfactory Bulbectomized Mice.Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer's Disease.Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.

P2860

Q26851680-B219C565-CCB9-47A9-97DA-5E4516550E2E Q28066691-64585709-C96B-4FAD-8AE1-B068F8F82725 Q30844298-5A7D054A-E80B-444C-81E8-7BFB4638206F Q33890252-D66E3E63-7038-40AD-89EA-ED19AF5DE827 Q33918218-CC7D89B4-8DA1-4730-AE0C-BFDE20C2DB45 Q34393100-020D0FBB-432B-4E44-AABC-D7EBD77D6F7F Q34764667-399F20C9-7E96-4F2E-8520-7C998757480D Q35639816-6599893E-AC83-459B-BDE5-FECAB3E7538B Q36036555-1F17636D-0DC7-4AE5-AB7B-467AB30FFD3B Q36248545-227D3EF3-95C9-4B83-8DD7-5DE1C1DBD7E5 Q36295526-95CA5B44-39A3-457B-BA53-82BF57E55A29 Q36869427-4DF7F8C3-6195-4EF3-BF58-ACBA54158153 Q36938297-46856AEB-C547-43BE-AD15-0C173C1A931A Q37172017-14F64215-1739-4F12-BF73-755ADB3275AC Q37999105-995A1046-088C-4527-90FE-A990B12BAC04 Q38012590-695D6C1B-187D-464A-9AF6-970634B0EADC Q38016165-01B78B19-D4EF-4E2D-8213-BCE30CA101EB Q38073138-EE537360-76C4-4B2C-8461-3EAE3918B515 Q38106507-79E66E1B-DA96-43B7-8284-5BAD9D5357D5 Q38186753-58B50FF8-B580-4FDD-8AF4-9A9EA10995F8 Q38212033-E9104EBA-D7D1-4E40-970E-BC5163C5A880 Q38353520-4EF5D751-D755-4A8D-B95D-AC4BE8077AE9 Q38497202-3EC9E945-888A-4A45-A1CC-82E91C978BD1 Q38747012-F329D69B-8B30-4EB6-8DED-013F96CBFF86 Q38751099-A1AB6392-D49B-4E3A-98C5-0600DEDD21E0 Q38809649-66EBC317-E958-4BC4-A8FC-42C70B4F6253 Q38950512-3E3C9304-43BF-4FC8-B875-8488D24E4249 Q39456457-0F6EADDB-5C0C-4C22-8A5F-DF6F28C02197 Q41472457-21BF318C-C952-415C-8D3B-203FF23FE2C6 Q42276130-A391060D-D7E2-465D-A3A9-8AC9CAA47AF1 Q42363726-3758C0A4-9CBC-40C1-BC4C-6D2504A083FF Q47865490-1B4834F8-551D-408E-891F-5006F82A013B Q47868277-C5306EA9-D5C2-41E5-81F0-514357932995 Q48759416-050D2D7C-B1C0-46BF-AA07-65835E996436 Q50582002-0E64309B-3635-43E6-AA76-6501DC30E048 Q51481172-8B397DF3-A877-404E-8D40-0BA3B29D53FA

P2860

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

http://www.wikidata.org/entity/Q28306851

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@ast

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@en

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@nl

type

label

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@ast

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@en

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@nl

prefLabel

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@ast

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@en

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@nl

P1433

Q28306851-0986B1B3-9166-4119-9EBA-7182DB513298

P1476

Q28306851-19EA6211-EE88-4376-B78E-073093F0FC1A

P2093

Q28306851-20751C37-CFF7-4254-8F84-8EAC1FBB1840

Q28306851-60F74D86-766E-4BC6-B099-5B29BEEBC8DA

Q28306851-737A8B0A-D6DC-4D68-9AE1-B12EA78C4D12

Q28306851-9B115210-049B-43D2-92CA-F4825CFF24EA

Q28306851-AEC264A9-E267-4D63-B35A-62162C8C2BF9

Q28306851-B1D09613-92CE-4FC2-99AD-4F09BD7F1B51

Q28306851-B89F7DF3-76B1-445D-8689-7D1F343F2F77

Q28306851-BB185E63-4016-4B4B-B60E-912C5975E10B

Q28306851-BD5D2DB1-CC3C-4935-AFA2-F2ED30A8614A

Q28306851-CD9E13D6-D7D0-494B-8B04-F87B93FFACA3

P2860

Q28306851-03B28442-D371-49E5-BD60-66A3665340A3

Q28306851-053CD0B3-CA4B-4A1D-BFDB-3EF347969DD0

Q28306851-0562B991-96AA-436A-B2E1-485961848A38

Q28306851-09F4820E-E519-4FB4-939C-7AAC3F62FBD0

Q28306851-14F4822C-5105-4290-B2C2-4A8A128BE050

Q28306851-185B8474-609D-4F1B-BCE2-21D35B0CE45E

Q28306851-191C9467-ACB7-4665-A69A-2D08F18D3A2C

Q28306851-1E7B2ADD-4232-41A9-9064-3B288F1BF5E9

Q28306851-1E7CA671-407D-4CA9-98F8-1FB28B298FB2

Q28306851-1F5747D3-18AF-416F-A162-6FA2E9E798BD

P304

Q28306851-A22A4746-BFFE-402E-A082-42274D199FEF

P31

Q28306851-C66A507C-467A-4857-A39B-F8BC81FF1E0A

P3181

Q28306851-134BB341-5C1D-4E9B-A344-226CFB42069E

P356

Q28306851-88D955DB-38F6-4E19-8610-23586E692BD1

P407

Q28306851-ACBA9636-4BAE-4528-9921-B11B302F8608

P433

Q28306851-F0160288-16F2-482B-A760-58BF72010507

P478

Q28306851-302A84D8-E730-429E-AEC7-9F72133BE0C4

P577

Q28306851-327B9C60-D77B-4321-918C-4B03AEA569FB

P5875

Q28306851-5EA86464-B8AA-4E51-86AE-1657B13577BC

P698

Q28306851-DB201593-242E-4352-B751-D4EF0F43257F

P921

Q28306851-7DEB3AAA-DD82-4E03-B9EA-1A1DD7CB5F52

P3181

P356

P1433

Annals of Neurology

P1476

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

@en

P2093

Eri Himeno

http://www.w3.org/2001/XMLSchema#string

Frank M LaFerla

http://www.w3.org/2001/XMLSchema#string

Jun-ichi Kira

http://www.w3.org/2001/XMLSchema#string

Katsue Miyoshi

http://www.w3.org/2001/XMLSchema#string

Kyoko Motomura

http://www.w3.org/2001/XMLSchema#string

Linqing Ma

http://www.w3.org/2001/XMLSchema#string

Naoko Soejima

http://www.w3.org/2001/XMLSchema#string

Nobutaka Sakae

http://www.w3.org/2001/XMLSchema#string

Norimichi Nakamura

http://www.w3.org/2001/XMLSchema#string

Ryo Yamasaki

http://www.w3.org/2001/XMLSchema#string

P2860

beta-Amyloid degradation and Alzheimer's disease

New Class of Inhibitors of Amyloid-beta Fibril Formation. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASE

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior

Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine

The ubiquitin-proteasome system in Alzheimer's disease

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

Intracellular amyloid-beta in Alzheimer's disease

gamma-Secretase dependent production of intracellular domains is reduced in adult compared to embryonic rat brain membranes

Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease.

Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology

P304

248-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4215240

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ANA.22319

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227697806

http://www.w3.org/2001/XMLSchema#string

P698

21387370

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease